Home/News/Tesamorelin

Growth Hormone Axis

GHRH Analog

Tesamorelin (Egrifta): The GHRH Analog Deep Dive

Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH) and the only therapy FDA-approved specifically to reduce excess visceral fat in HIV-associated lipodystrophy. Rather than replacing growth hormone, it prompts the body to make its own — preserving the natural feedback loop. This article covers its history, the pivotal trials, the FDA approval process, its mechanism, and its known and speculative downstream effects.

Educational content. Tesamorelin (Egrifta SV) is FDA-approved only for HIV-associated lipodystrophy and must be prescribed and monitored by a licensed clinician. Other uses are off-label or research-grade. This article is educational and not medical advice.

Brand name

Egrifta / Egrifta SV

Drug class

GHRH analog

FDA approved

Yes — HIV lipodystrophy (2010)

Route

Daily subcutaneous injection

History & Discovery

1980s

GHRH is characterized

Growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic peptide, was identified as the natural trigger for pituitary GH secretion. The problem for drug development: native GHRH is degraded within minutes by the enzyme DPP-4.

1990s–2000s

Theratechnologies engineers tesamorelin

The Canadian company Theratechnologies created a stabilized GHRH(1–44) analog by adding a trans-3-hexenoic acid group to the N-terminus, protecting it from enzymatic cleavage and extending its functional half-life enough to be a once-daily therapy.

2000s

Targeting HIV lipodystrophy

A specific unmet need drove its development: many people on antiretroviral therapy accumulate excess visceral abdominal fat (HIV-associated lipodystrophy), which is metabolically harmful and distressing. Tesamorelin was studied to reduce this visceral fat.

2010

FDA approval

Following two pivotal Phase 3 trials, the FDA approved tesamorelin (Egrifta) in November 2010 — making it the first and only therapy approved specifically to reduce excess visceral adipose tissue in HIV-associated lipodystrophy.

Clinical Trial Evidence

Phase 3 Study 1

Phase 3

N: 412 HIV adults with lipodystrophyDuration: 26 weeks

Tesamorelin 2 mg/day reduced visceral adipose tissue (trunk fat) by ~−17.8% vs +3.0% placebo (p<0.001), with significant IGF-1 increases and no reduction in beneficial limb fat.

Phase 3 Study 2

Phase 3

N: 272 HIV adultsDuration: 26 weeks

Replicated the visceral fat reduction of Study 1. Responders also reported improved body-image outcomes — the basis for FDA approval.

Extension (Falutz et al., 2010)

Extension

N: Subset from Phase 3Duration: 52 weeks

Visceral fat reduction was maintained at 52 weeks with continued therapy; stopping treatment led to fat returning toward baseline — confirming that ongoing dosing is required.

Cognitive Function (Friedman et al., 2021)

Phase 2

N: 152 older adultsDuration: 20 weeks

Tesamorelin improved a composite measure of executive function and memory with IGF-1 roughly doubling — broadening research interest beyond the metabolic indication.

FDA Approval Process

Approval for HIV lipodystrophy (Nov 2010)

The two replicate Phase 3 trials provided the efficacy and safety basis for FDA approval of Egrifta to reduce excess abdominal visceral fat in HIV-associated lipodystrophy — a narrow, well-defined indication.

Egrifta SV reformulation

A later reformulation (Egrifta SV) improved stability and simplified reconstitution and dosing, keeping the product current within the same approved indication.

Off-label and research use

Tesamorelin is approved ONLY for HIV lipodystrophy. Use for general visceral fat loss, anti-aging, or cognition is off-label or research-grade. Material sold as 'tesamorelin' for research outside a pharmacy is unapproved and unregulated.

Mechanism of Action

GHRH receptor agonism

Tesamorelin binds GHRH receptors on pituitary somatotroph cells with affinity essentially identical to native GHRH, triggering the cAMP/PKA cascade that releases the body's own growth hormone.

Stabilized half-life

The trans-3-hexenoic acid modification protects the N-terminal bond from DPP-4 cleavage, extending the functional half-life from minutes (native GHRH) to roughly 26–38 minutes — enough for once-daily dosing.

Preserved feedback loop

Because it stimulates the pituitary rather than supplying GH directly, the natural IGF-1 negative-feedback loop stays intact. When IGF-1 rises, it dampens further GH release — limiting the supraphysiological GH excess and acromegaly risk seen with direct rhGH injections.

Pulsatile GH pattern

Tesamorelin maintains a more physiological pulsatile GH secretion than exogenous GH, which produces a single sustained peak. Pulsatility is associated with better receptor sensitivity and a more favorable metabolic profile.

For a step-by-step walk through the entire GH axis and how tesamorelin fits into it, see our companion article How Tesamorelin Works: The GH Axis Explained.

Downstream Effects

Known / Documented

Significant visceral adipose tissue reduction (~18% in Phase 3)
Elevated IGF-1 maintained throughout treatment
Improved triglycerides and body-image scores in lipodystrophy
Cognitive improvement signals in older adults (Phase 2)
Injection-site reactions, arthralgia, and fluid retention/edema
Transient insulin resistance — glucose monitoring advised in at-risk patients

Speculative / Under Study

Visceral obesity outside HIV (Phase 2 signals; not an approved use)
Age-related GH decline ('somatopause') restoration
Cognitive aging and neuroprotection via the GH/IGF-1 axis
NAFLD/fatty liver improvement through visceral fat reduction
Long-term safety beyond ~1 year of continuous use is not well characterized
Theoretical IGF-1-related risks require monitoring and are not fully resolved